anthracycline induced cardiomyopathy
DESCRIPTION
Anthracycline induced Cardiomyopathy. AM Report December 11 2009. Chemotherapy and Cardiotoxicity. Anthracyclines Herceptin Antimetabolites 5-fluorouracil - coronary vasospasm Fludarabine - high dose for BMT conditioning Vinca alkaloids - hypertension, myocardial ischemia - PowerPoint PPT PresentationTRANSCRIPT
Anthracycline induced Cardiomyopathy
Anthracycline induced Cardiomyopathy
AM Report
December 11 2009AM Report
December 11 2009
Chemotherapy and Cardiotoxicity
Chemotherapy and Cardiotoxicity
Anthracyclines Herceptin Antimetabolites
5-fluorouracil - coronary vasospasm Fludarabine - high dose for BMT conditioning
Vinca alkaloids - hypertension, myocardial ischemia Taxanes - conduction abnormalities Cyclophosphamide - cardiomyopathy Bleomycin - pericarditis Mitomycin C - heart failure Monoclonal antibodies
Anthracyclines Herceptin Antimetabolites
5-fluorouracil - coronary vasospasm Fludarabine - high dose for BMT conditioning
Vinca alkaloids - hypertension, myocardial ischemia Taxanes - conduction abnormalities Cyclophosphamide - cardiomyopathy Bleomycin - pericarditis Mitomycin C - heart failure Monoclonal antibodies
History of Anthracycline useHistory of Anthracycline use
Fermentation product of Streptomyces peucetius
Daunomycin and doxorubicin devolped in 1960s
Clinical Uses breast and esophageal
carcinomas osteosarcoma, Kaposi's sarcoma and soft-
tissue sarcomas Hodgkin's and non-
Hodgkin's lymphomas
Fermentation product of Streptomyces peucetius
Daunomycin and doxorubicin devolped in 1960s
Clinical Uses breast and esophageal
carcinomas osteosarcoma, Kaposi's sarcoma and soft-
tissue sarcomas Hodgkin's and non-
Hodgkin's lymphomas Doxorubicin
MechanismMechanism
Therapuetic Intercalating between base
pairs of the DNA/RNA Inhibits topoiosomerase II
enzyme
Cardiotoxicity Production of toxic oxygenハ free radicals and an increase in oxidative stress
Loss of myofibrils and the vacuolization of cytoplasm
Therapuetic Intercalating between base
pairs of the DNA/RNA Inhibits topoiosomerase II
enzyme
Cardiotoxicity Production of toxic oxygenハ free radicals and an increase in oxidative stress
Loss of myofibrils and the vacuolization of cytoplasm
Risk Factors - Cumulative doseRisk Factors - Cumulative dose
0
20
40
60
80
100
Inc
ide
nc
e o
f C
HF
(%
)
< 350 550 600 700Cumulative Dose (mg/m2)
Incidence of CHF as a Function of Cumulative Doxorubicin Dose
0
20
40
60
80
100
Inc
ide
nc
e o
f C
HF
(%
)
< 350 550 600 700Cumulative Dose (mg/m2)
Incidence of CHF as a Function of Cumulative Doxorubicin Dose
Risk FactorsRisk Factors
Age <3 years of age and >70 years of age
Previous/Concurrent Radiation Concomitant chemotherapy
Herceptin and taxols Bone Marrow Transplant Cardiac Risk Factors
Age <3 years of age and >70 years of age
Previous/Concurrent Radiation Concomitant chemotherapy
Herceptin and taxols Bone Marrow Transplant Cardiac Risk Factors
Clinical ManifestationsClinical Manifestations
Acute - during infusion to 1 week Arrhythmias Ventricular dysfunction Pericarditis/myocarditis
Early - < 1 year Dose-related cardomyopathy
Late
Acute - during infusion to 1 week Arrhythmias Ventricular dysfunction Pericarditis/myocarditis
Early - < 1 year Dose-related cardomyopathy
Late
MonitoringMonitoring
Serial noninvasive monitoring of LVEF Radionuclide angiography (MUGA) Echocardiography
Exercise stress radionuclide ventriculography Biomarkers
Serum troponins BNP/pro-BNP
Endomyocardial Biopsy
Serial noninvasive monitoring of LVEF Radionuclide angiography (MUGA) Echocardiography
Exercise stress radionuclide ventriculography Biomarkers
Serum troponins BNP/pro-BNP
Endomyocardial Biopsy
MonitoringMonitoring
Normal EF Baseline (prior to 100 mg/m2) 2nd study after 250 to 300 mg/m2 3rd at 400-450 mg/m2 Sequential studies prior to each additional dose
EF 30-50% EF study prior to each dose
EF < 30% - recommend against initiating Discontinue doxorubicin for decrease in EF
>10% or absolute < 30%
Normal EF Baseline (prior to 100 mg/m2) 2nd study after 250 to 300 mg/m2 3rd at 400-450 mg/m2 Sequential studies prior to each additional dose
EF 30-50% EF study prior to each dose
EF < 30% - recommend against initiating Discontinue doxorubicin for decrease in EF
>10% or absolute < 30%
PreventionPrevention
Altering infusion protocol Alternate anthracycline derivatives Liposomal preparations Dexrazoxane - metal-chelating agent Beta-blockers ACE inhibitors
Altering infusion protocol Alternate anthracycline derivatives Liposomal preparations Dexrazoxane - metal-chelating agent Beta-blockers ACE inhibitors
Prognosis and TreatmentPrognosis and Treatment
Prognosis Mortality rates of > 30% in early studies
Treatment ACE inhibitors Traditional Heart failure Management Heart Transplant
Prognosis Mortality rates of > 30% in early studies
Treatment ACE inhibitors Traditional Heart failure Management Heart Transplant
RefrencesRefrences
Up-to-Date Cancer Medicine 6 CHEST February 1999 vol. 115 no. 2 569-571 Schwartz, RG, McKenzie, WB, Alexander, J, et al. Congestive heart
failure and left ventricular dysfunction complication doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82:1109.
Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother. 2008 Jan;42(1):99-104.
Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K. Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol. 2007;46(5):576-80.
Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998 Sep 24;339(13):900-5.
Up-to-Date Cancer Medicine 6 CHEST February 1999 vol. 115 no. 2 569-571 Schwartz, RG, McKenzie, WB, Alexander, J, et al. Congestive heart
failure and left ventricular dysfunction complication doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82:1109.
Jannazzo A, Hoffman J, Lutz M. Monitoring of anthracycline-induced cardiotoxicity. Ann Pharmacother. 2008 Jan;42(1):99-104.
Appel JM, Nielsen D, Zerahn B, Jensen BV, Skagen K. Anthracycline-induced chronic cardiotoxicity and heart failure. Acta Oncol. 2007;46(5):576-80.
Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998 Sep 24;339(13):900-5.